Literature DB >> 11739533

Role of TGFbeta in development of spontaneous autoimmune thyroiditis in NOD.H-2h4 mice.

H Braley-Mullen1, K Chen, Y Wei, S Yu.   

Abstract

Nearly 100% of NOD.H-2h4 mice develop spontaneous autoimmune thyroiditis (SAT) and produce anti-mouse thyroglobulin autoantibodies when they receive 0.05% NaI in their drinking water beginning at 8 wk of age. Our previous studies showed that TGFbeta1 mRNA was constitutively expressed in thyroids and spleens of normal NOD.H-2h4 mice but not other strains of mice. To determine whether TGFbeta might have a role in SAT, mice were given anti-TGFbeta mAb at various times during development of SAT. Anti-TGFbeta markedly inhibited development of SAT and production of anti-mouse thyroglobulin IgG1 autoantibodies. Anti-TGFbeta was most effective in inhibiting SAT when given during the time thyroid lesions were developing, i.e., starting 4 wk after administration of NaI water. The active form of the TGFbeta1 protein was present in thyroids of mice with SAT but not in normal NOD.H-2h4 thyroids. However, thyrocytes of normal NOD.H-2h4 thyroids did express latent TGFbeta1. TGFbeta1 protein expression in the thyroid correlated with SAT severity scores, and administration of anti-TGFbeta inhibited TGFbeta1 protein expression in both the thyroid and spleen. TGFbeta1 was produced primarily by inflammatory cells and was primarily localized in areas of the thyroid containing clusters of CD4(+) T and B cells. Depletion of CD8(+) T cells had no effect on TGFbeta1 protein expression. Activation of splenic T cells was apparently not inhibited by anti-TGFbeta, because up-regulation of mRNA for cytokines and other T cell activation markers was similar for control and anti-TGFbeta-treated mice. TGFbeta1 may function by promoting migration to, or retention of, inflammatory cells in the thyroid.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739533     DOI: 10.4049/jimmunol.167.12.7111

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  TGF-β blockade does not improve control of an established persistent viral infection.

Authors:  Tobias Boettler; Yang Cheng; Katrin Ehrhardt; Matthias von Herrath
Journal:  Viral Immunol       Date:  2012-05-23       Impact factor: 2.257

2.  Adenovirus-mediated gene delivery of interleukin-10, but not transforming growth factor beta, ameliorates the induction of Graves' hyperthyroidism in BALB/c mice.

Authors:  O Saitoh; Y Mizutori; N Takamura; H Yamasaki; A Kita; H Kuwahara; Y Nagayama
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

3.  TGF-beta signaling is required for the function of insulin-reactive T regulatory cells.

Authors:  Wei Du; F Susan Wong; Ming O Li; Jian Peng; Hao Qi; Richard A Flavell; Robert Sherwin; Li Wen
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

4.  Reduced effectiveness of CD4+Foxp3+ regulatory T cells in CD28-deficient NOD.H-2h4 mice leads to increased severity of spontaneous autoimmune thyroiditis.

Authors:  Jason S Ellis; So-Hee Hong; Habib Zaghouani; Helen Braley-Mullen
Journal:  J Immunol       Date:  2013-10-04       Impact factor: 5.422

5.  Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage.

Authors:  Vijay Saxena; Douglas W Lienesch; Min Zhou; Ramireddy Bommireddy; Mohamad Azhar; Thomas Doetschman; Ram Raj Singh
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

6.  Auricular chondritis in NOD.DQ8.Abetao (Ag7-/-) transgenic mice resembles human relapsing polychondritis.

Authors:  Veena Taneja; Marie Griffiths; Marshall Behrens; Harvinder S Luthra; Chella S David
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

7.  Alpha lipoic acid attenuates radiation-induced thyroid injury in rats.

Authors:  Jung Hwa Jung; Jaehoon Jung; Soo Kyoung Kim; Seung Hoon Woo; Ki Mun Kang; Bae-Kwon Jeong; Myeong Hee Jung; Jin Hyun Kim; Jong Ryeal Hahm
Journal:  PLoS One       Date:  2014-11-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.